ADARx Pharmaceuticals Inc. rose 10.5% on Thursday, November 19, 2026, on 556,300 shares. No headline about ADRX came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.
ADARx Pharmaceuticals Inc. (ADRX:NASDAQ) closed at $12.79 on November 20, 2026, down 9.68% on the day. The stock trades 44.9% below its 52-week high of $23.21 and 2.3% above its 52-week low of $12.50. Over the past year, it lost 33.9%. ADARx Pharmaceuticals Inc. is part of the Health Care sector.
In 40 trading sessions since September 28, 2026, ADRX closed higher on 15 days (38%). Its best day was November 12, 2026 (+12.11%) and its worst was November 5, 2026 (-11.16%). The stock moved 10% or more in a single session 3 times.
ADARx Pharmaceuticals, Inc. is a late-stage biotechnology company dedicated to transforming cutting-edge science into next-generation siRNA therapeutics. We have developed technology designed to control the expression of specific disease drivers with highly selective RNA targeted therapies with the goal of delivering life-changing treatments for patients with unmet medical needs. ADARx is focused on advancing and expanding a deep pipeline of highly potent, durable and selective RNA-targeted therapeutic candidates, developing product candidates for the treatment of complement-mediated, genetic, cardiovascular, thrombosis, central nervous system and metabolic (obesity) diseases. In addition to our wholly-owned programs, we have entered into a collaboration and license option agreement with AbbVie to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, including neuroscience, immunology and oncology.
Find more stocks like ADRX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.